Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 3, 2009, Pages 908-918

  Chen, Chen ^a   Li, Guiling ^a   Liao, Wanmin ^a   Wu, Jun ^a   Liu, Liu ^a   Ma, Ding ^a   Zhou, Jianfeng ^a   Elbekai, Reem H ^b   Edin, Matthew L ^b   Zeldin, Darryl C ^b   Dao, Wen Wang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD82 ANTIGEN; CYTOCHROME P450 2J2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPOXYICOSATRIENOIC ACID; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TERFENADINE; TERFENADINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TERFENADINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66749159294     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.152017     Document Type: Article

References (31)

1. Anagnostopoulos K, Tentes I, and Kortsaris AH (2008) Cell signaling in cancer. J BUON 13:17-22.
2. Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, and Szepeshazi K (2002) Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci U S A 99:3836-3841. (Pubitemid 34252192)
3. 1-receptor activation of nuclear factor-B: roles for G- and Gq/11-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 60:1133-1142.
4. Capdevila JH, Falck JR, and Harris RC (2000) Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41:163-181. (Pubitemid 30117856)
5. Ciprandi G, Passalacqua G, and Canonica GW (1999) Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy 29:49-53. (Pubitemid 29333332)
6. Enayetallah AE, French RA, Thibodeau MS, and Grant DF (2004) Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447-454. (Pubitemid 38420379)
7. Fishman DA, Liu Y, Ellerbroek SM, and Stack MS (2001) Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61:3194-3199. (Pubitemid 32691975)
8. Jangi SM, Díaz-Pérez JL, Ochoa-Lizarralde B, Martín-Ruiz I, Asumendi A, Pérez- Yarza G, Gardeazabal J, Díaz-Ramón JL, and Boyano MD (2006) H1 histamine receptor antagonists induce genotoxic and caspase-2-dependent apoptosis in human melanoma cells. Carcinogenesis 27:1787-1796. (Pubitemid 44288661)
9. 1 histamine receptors. Carcinogenesis 29:500-509.
10. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, and Wang DW (2005) Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:4707-4715. (Pubitemid 40740807)
11. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, et al. (2007) Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res 67:6665-6674.
12. Karara A, Makita K, Jacobson HR, Falck JR, Guengerich FP, DuBois RN, and Capdevila JH (1993) Molecular cloning, expression, and enzymatic characterization of the rat kidney cytochrome P-450 arachidonic acid epoxygenase. J Biol Chem 268:13565-13570. (Pubitemid 23307786)
13. Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13:472-482.
14. Kroetz DL and Zeldin DC (2002) Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 13:273-283. (Pubitemid 34592284)
15. Lafite P, Dijols S, Buisson D, Macherey AC, Zeldin DC, Dansette PM, and Mansuy D (2006) Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett 16:2777-2780.
16. Lafite P, Dijols S, Zeldin DC, Dansette PM, and Mansuy D (2007) Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys 464:155-168. (Pubitemid 47210920)
17. Leurs R, Church MK, and Taglialatela M (2002) H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 32:489-498. (Pubitemid 34429565)
18. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
19. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279. (Pubitemid 29398616)
20. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185. (Pubitemid 34654217)
21. Roy S, Bayly CI, Gareau Y, Houtzager VM, Kargman S, Keen SL, Rowland K, Seiden IM, Thornberry NA, and Nicholson DW (2001) Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci U S A 98:6132-6137.
22. + channels and p42/p44 MAPK pathway. Circ Res 95:506-514.
23. Simons FE (2004) Advances in H1-antihistamines. N Engl J Med 351:2203-2217.
24. Triggiani M, Gentile M, Secondo A, Granata F, Oriente A, Taglialatela M, Annunziato L, and Marone G (2001) Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 166:4083-4091. (Pubitemid 32224939)
25. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, and Zeldin DC (2003) Up-regulation of endothelial nitric-oxide synthase by endotheliumderived hyperpolarizing factor involves mitogen activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther 307:753-764. (Pubitemid 37310693)
26. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, and Zeldin DC (2005) Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via MAP kinase and PI3 kinase/Akt signaling pathways. J Pharmacol Exp Ther 314:522-532.
27. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, and Zeldin DC (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272:272:12551-12559. (Pubitemid 27203348)
28. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468. (Pubitemid 26065653)
29. Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, et al. (2007) Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol 293:H142-H151.
30. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276:36059-36062. (Pubitemid 33653697)
31. Zipin A, Israeli-Amit M, Meshel T, Sagi-Assif O, Yron I, Lifshitz V, Bacharach E, Smorodinsky NI, Many A, Czernilofsky PA, et al. (2004) Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res 64:6571-6578. (Pubitemid 39297916)